PO042 Early-esli study: from early add-on to monotherapy with eslicarbazepine acetate

• Published in: Journal of neurology, neurosurgery and psychiatry Vol. 88; no. Suppl 1; pp. A22 - A23
• Main Authors: Villanueva, V, Gómez, A, Garcés, M, Bermejo, P, Montoya, J, Toledo, M, López-González, FJ, Rodriguez, X, Campos, D, Martínez, P, Giner, P, Zurita, J, Rodríguez-Uranga, J, Ojeda, J, Mauri, JA, Ruiz-Giménez, J, Poza, JJ, Massot, A, Bonet, M
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.12.2017
• Subjects: Consortia; Convulsions & seizures; Dementia; Epilepsy; Fistula; Genomes; Population
• ISSN: 0022-3050; 1468-330X
• DOI: 10.1136/jnnp-2017-ABN.75

PurposeReal-life experience with eslicarbazepine acetate (ESL) after first monotherapy failure in a large series of patients with partial epilepsyMethodMulticenter, retrospective, 1 year, observational study. Inclusion criteria: 1) patients older than 18 years; 2) partial-onset seizures; 3) Failure of first monotherapy for any reason (efficacy, tolerability, compliance). Time-points for revision were at 3, 6 and 12 months. Main objectives were to assess efficacy and tolerability.ResultsA total of 253 patients were collected. The one-year retention rate was 92.9%. The mean dose after 12 months was 903.6±267 mg (range 400–1600). At 12 months, the percentage of seizure-free patients was 62.3%, 82.5% were responders and 5.6% did worse. Along the follow-up 31.6% of the patients reported adverse events and 3.6% discontinued for that reason. The main side effects were somnolence (8.7%) and dizziness (5.1%). A total of 127 patients (50.2%) were converted to monotherapy for at least 6 months. In this group, 77.2% were seizure-free and 29.1% of the patients reported AE after 1 year.ConclusionESL outcome along 1 year follow-up after first monotherapy failure showed an optimal efficacy and tolerability profile. Half of patients were converted to monotherapy and followed for at least 6 months.